Standard therapy for high grade glioma is a topic that is evolving, timely, and relevant. Guest Editors Isaac Yang, MD and Seunggu Han, MD have assembled a group of experts to highlight the latest updates on various forms of management of high grade glioma. Some of the articles included in this issue focus on Extent of Resection for Glioblastoma; Role of adjuvant radiation therapy; Survival benefit of the Temozolomide protocol; Alternative chemotherapeutic agents; The role of avastin; Radiology; Pseuodprogression and Treatment effect; Pathology; Medical Management; Management of insular gliomas; Use of motor mapping; GBM treatment with clinical trials for surgical resection; Clinical trials with immunotherapy; Clinical trials for small molecule inhibitors; Future role of CED for GBM treatment; Application of a vault nanoparticle therapy for GBM therapy; Management of high grade gliomas in pediatric populations; Targeting Glioma Stem Like Cells with a focus on CD 133; and Potential Role for STAT3 inhibitors in glioblastoma.
Please Note: This is an On Demand product, delivery may take up to 11 working days after payment has been received.
Authors
Isaac Yang MD, UCLA Department of Neurosurgery, Associate Professor, Director of Medical Student Education, Jonsson Comprehensive Cancer Center, Los Angeles, California, USA.Dr. Yang is an Associate Professor in the Department of Neurosurgery at UCLA. He has been awarded the AANS Tumor Investigator Award and the Exceptional Physician Award. Dr. Yang is a nationally recognized leader in neurosurgery and brain tumors, serving on both executive committees and editorial boards. He has published more than 100 publications, and has authored multiple book chapters and several textbooks, including a Service Minded Physician.
Seunggu J. Han
University of California San Francisco
UCSF Department of Neurological Surgery
